DAFTAR PUSTAKA

Akbarzadeh-Jahromi, M., Zare, Z., Aslani, F.S., & Torabinezhad, S., 2020. Evaluation of pten and ki67 expression in typical and atypical endometriosis and endometriosis associated ovarian cancer. *Shiraz E Med. J.* 21: 1–7. doi:10.5812/semj.99291

Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., Yuan, M., et al., 2014. inhibits downstream Akt signaling to suppress tumorigenesis 15: 1340–1350. doi:10.1038/ncb2860.Sin1

Balan, R.A., Căruntu, I.D., Giușcă, S.E., Lozneanu, L., Păvăleanu, I., Socolov, R.V., et al., 2017. Immunohistochemical significance of ER alpha, inhibin a, calretinin, and Ki67 expression in granulosa cell ovarian tumors. *Rom. J. Morphol. Embryol.* 58: 753–760.

Battifora, H., 1986. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. *Lab. Invest.* 55: 244–248.

Blagden, S.P., 2015. Harnessing pandemonium: The clinical implications of tumor heterogeneity in ovarian cancer. *Front. Oncol.* 5: 1–6. doi:10.3389/fonc.2015.00149

Booth, D.G., Takagi, M., Sanchez-Pulido, L., Petfalski, E., Vargiu, G., Samejima, K., et al., 2014. Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery. *Elife* 3: 1–22. doi:10.7554/elife.01641

Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L., & Cheng, W.F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One* 13: 1–11. doi:10.1371/journal.pone.0194993

Chen, A., Laskar-Levy, O., Ben-Aroya, N., & Koch, Y., 2001. Transcriptional regulation of the human GnRH II gene is mediated by a putative cAMP response element. *Endocrinology* 142: 3483–3492. doi:10.1210/endo.142.8.8302

Chen, A., Ziv, K., Laskar-Levy, O., & Koch, Y., 2002. The transcription of the hGNRH-I and hGNRH-II genes in human neuronal cells is differentially regulated by estrogen. *J. Mol. Neurosci.* 18: 65–76. doi:10.1385/jmn:18:1-2:65

Chen, C.-L., Cheung, L.W.T., Lau, M.-T., Choi, J.-H., Auersperg, N., Wang, H.-S., et al., 2007. Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. *Endocrine* 31: 311–320. doi:10.1007/s12020-007-0041-8

Chen, C.P., & Lu, X., 2022. Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis. *J. Int. Med. Res.* 50. doi:10.1177/03000605221082895

Chen, M., Yao, S., Cao, Q., Xia, M., Liu, J., & He, M., 2017. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: An 11-year cohort study of Chinese patients. *Oncotarget* 8: 107877–107885. doi:10.18632/oncotarget.14112

Cheung, L.W.T., & Wong, A.S.T., 2008. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. *FEBS J.* 275: 5479–5495. doi:https://doi.org/10.1111/j.1742-4658.2008.06677.x

Chierico, L., Rizzello, L., Guan, L., Joseph, A.S., Lewis, A., & Battaglia, G., 2017. The role of the two splice variants and extranuclear pathway on Ki-67 regulation in non-cancer and cancer cells. *PLoS One* 12: 1–20. doi:10.1371/journal.pone.0171815

Choi, J.H., Choi, K.C., Auersperg, N., & Leung, P.C.K., 2006a. Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid by gonadotropins in human immortalized ovarian surface epithelium and ovarian cancer cells. *Endocr. Relat. Cancer* 13: 641–651. doi:10.1677/erc.1.01057

Choi, J.H., Gilks, C.B., Auersperg, N., & Leung, P.C.K., 2006b. Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. *J. Clin. Endocrinol. Metab.* 91: 4562–4570. doi:10.1210/jc.2006-1147

Choi, K.C., Auersperg, N., & Leung, P.C., 2001. Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. *J. Clin. Endocrinol. Metab.* 86: 5075–5078. doi:10.1210/jcem.86.10.8100

Chou, C.S., MacCalman, C.D., & Leung, P.C.K., 2003. Differential effects of gonadotropin-releasing hormone I and II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human decidual stromal cells in vitro. *J. Clin. Endocrinol. Metab.* 88: 3806–3815. doi:10.1210/jc.2002-021955

Currie, J.C., Demeule, M., Charfi, C., Zgheib, A., Larocque, A., Danalache, B.A., et al., 2022. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. *Cancers (Basel).* 14. doi:10.3390/cancers14081877

Cuylen, S., Blaukopf, C., Politi, A.Z., Muller-Reichert, T., Neumann, B., Poser, I., et al., 2016. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. *Nature* 535: 308–312. doi:10.1038/nature18610

Darby, S., Stockley, J., Khan, M.M., Robson, C.N., Leung, H.Y., & Gnanapragasam, V.J., 2007. Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. *Endocrine-Related Cancer Endocr Relat Cancer* 14: 613–624. doi:10.1677/ERC-07-0041

Davis, S.R., Lambrinoudaki, I., Lumsden, M., Mishra, G.D., Pal, L., Rees, M., et al., 2015. Menopause. *Nat. Rev. Dis. Prim.* 1: 15004. doi:10.1038/nrdp.2015.4

De Castro, I.J., Budzak, J., Di Giacinto, M.L., Ligammari, L., Gokhan, E., Spanos, C., et al., 2017. Repo-Man/PP1 regulates heterochromatin formation in interphase. *Nat. Commun.* 8. doi:10.1038/ncomms14048

Densmore, V.S., & Urbanski, H.F., 2004. Effect of 17β-estradiol on hypothalamic GnRH-II gene expression in the female rhesus macaque. *J. Mol. Endocrinol.* 33: 145–153. doi:10.1677/jme.0.0330145

Desaulniers, A.T., Cederberg, R.A., Lents, C.A., & White, B.R., 2017a. Expression and role of gonadotropin-releasing hormone 2 and its receptor in mammals. *Front. Endocrinol. (Lausanne).* 8: 1–25. doi:10.3389/fendo.2017.00269

Desaulniers, A.T., Cederberg, R.A., Lents, C.A., & White, B.R., 2017b. Expression and role of gonadotropin-releasing hormone 2 and its receptor in mammals. *Front. Endocrinol. (Lausanne).* 8. doi:10.3389/fendo.2017.00269

Devouassoux-Shisheboran, M., & Genestie, C., 2015. Pathobiology of ovarian carcinomas. *Chin. J. Cancer* 34: 50–55. doi:10.5732/cjc.014.10273

Dewi, I.G.A.S.M., Susraini, A.A.A.N., & Ekawati, N.P., 2020. Her2/neu and ki-67 as prognostic factors in serous type ovarian carcinoma. *Bali Med. J.* 9: 567–571. doi:10.15562/bmj.v9i2.1926

Dong-Ki, K., Ji, S.Y., Kaushik, M., Jong-Ik, H., Kyungjin, K., Dongseung, S., et al., 2009. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. *Cancer Res.* 69: 923–931. doi:10.1158/0008-5472.CAN-08-2115

Dowsett, M., Nielsen, T.O., A'Hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., et al., 2011. Assessment of Ki67 in Breast Cancer: Recommendations from the international Ki67 in breast cancer working Group. *J. Natl. Cancer Inst.* 103: 1656–1664. doi:10.1093/jnci/djr393

Duffy, M.J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., et al., 2017. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). *Eur. J. Cancer* 75: 284–298. doi:10.1016/j.ejca.2017.01.017

Edge, S.B., & Compton, C.C., 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann. Surg. Oncol.* doi:10.1245/s10434-010-0985-4

Eicke, N., Günthert, A., Viereck, V., Sebold, D., Béhé, M., Becker, T., et al., 2005. GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. *Eur. J. Endocrinol.* 153: 605–612. doi:10.1530/eje.1.02005

Eicke, N., Günthert, A.R., Emons, G., & Gründker, C., 2006. GnRH-II agonist [D-

Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. *Int. J. Oncol.* 29: 1223–1229. doi:10.3892/ijo.29.5.1223

Elgamal, A., & Amin, L., 2022. Evaluation of Topical Application of Platelets Rich Plasma and Hyaluronic Acid on the Healing of Experimentally Induced Tongue Ulcer. *Egypt. Dent. J.* 68: 355–369. doi:10.21608/edj.2021.97512.1798

Emons, G., Ortmann, O., Schulz, K.D., & Schally, A. V, 1997. Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells. *Trends Endocrinol. Metab.* 8: 355–362. doi:10.1016/s1043-2760(97)00155-0

Etikan, I., Musa, S.A., & Alkassim, R.S., 2017. Comparison of Convenience Sampling and Purposive Sampling Comparison of Convenience Sampling and Purposive Sampling. doi:10.11648/j.ajtas.20160501.11

Feng, Z., Wen, H., Bi, R., Ju, X., Chen, X., Yang, W., et al., 2016. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. *Sci. Rep.* 6: 1–9. doi:10.1038/srep25408

Feng, Z., Wen, H., Ju, X., Bi, R., Chen, X., Yang, W., et al., 2017. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). *J. Ovarian Res.* 10: 1–8. doi:10.1186/s13048-016-0300-5

Fister, S., Günthert, A.R., Aicher, B., Paulini, K.W., Emons, G., & Gründker, C., 2009. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein bax. *Cancer Res.* 69: 6473–6481. doi:10.1158/0008-5472.CAN-08-4657

Fister, S., Günthert, A.R., Emons, G., & Gründker, C., 2007. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. *Cancer Res.* 67: 1750–1756. doi:10.1158/0008-5472.CAN-06-3222

Fontana, F., Marzagalli, M., Marelli, M.M., Raimondi, M., Moretti, R.M., & Limonta, P., 2020. Gonadotropin-releasing hormone receptors in prostate cancer: Molecular aspects and biological functions. *Int. J. Mol. Sci.* 21: 1–23. doi:10.3390/ijms21249511

Gault, P.M., Maudsley, S., & Lincoln, G.A., 2003. Evidence that gonadotropin-releasing hormone II is not a physiological regulator of gonadotropin secretion in mammals. *J. Neuroendocrinol.* 15: 831–839. doi:10.1046/j.1365-2826.2003.01065.x

Gerdes, J., Li, L., Schlueter, C., Duchrow, M., Wohlenberg, C., Gerlach, C., et al., 1991. Immunobiochemical and molecular biologic characterization of the cell

proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. *Am. J. Pathol.* 138: 867–873.

Ghaly, H.S.A., & Varamini, P., 2021. New drug delivery strategies targeting the GnRH receptor in breast and other cancers. *Endocr. Relat. Cancer* 28: R251–R269. doi:10.1530/ERC-20-0442

Gong, T.-T., Wu, Q.-J., Vogtmann, E., Lin, B., & Wang, Y.-L., 2013. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. *Int. J. cancer* 132: 2894–2900. doi:10.1002/ijc.27952

Grabowski, J.P., Glajzer, J., Richter, R., Plett, H., Muallem, M.-Z., Braicu, E.I., et al., 2021. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer. *Int. J. Gynecol. Cancer* 31: 98 LP – 103. doi:10.1136/ijgc-2020-001950

Grabowski, J.P., Martinez Vila, C., Richter, R., Taube, E., Plett, H., Braicu, E., et al., 2020. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. *Int. J. Gynecol. cancer Off. J. Int. Gynecol. Cancer Soc.* 30: 498–503. doi:10.1136/ijgc-2019-000976

Gründker; Emons, G., 2021. Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.

Gründker, C., & Emons, G., 2003. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer 7: 1–7.

Gründker, C., Günthert, A.R., Millar, R.P., & Emons, G., 2002a. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. *J. Clin. Endocrinol. Metab.* 87: 1427–1430. doi:10.1210/jc.87.3.1427

Gründker, C., Günthert, A.R., Millar, R.P., & Emons, G., 2002. Expression of Gonadotropin-Releasing Hormone II (GnRH-II) Receptor in Human Endometrial and Ovarian Cancer Cells and Effects of GnRH-II on Tumor Cell Proliferation. *J. Clin. Endocrinol. Metab.* 87: 1427–1430. doi:10.1210/jcem.87.3.8437

Gründker, C., Günthert, A.R., Westphalen, S., & Emons, G., 2002b. Biology of the gonadotropin-releasing hormone system in gynecological cancers. *Eur. J. Endocrinol.* 146: 1–14. doi:10.1530/eje.0.1460001

Gründker, C., Schlotawa, L., Viereck, V., Eicke, N., Horst, A., Kairies, B., et al., 2004. Antiproliferative effects of the GnRH antagonist cetrorelix and GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. *Eur. J. Endocrinol.* 151: 141–149. doi:10.1530/eje.0.1510141

Gründker, C., Völker, P., & Emons, G., 2001. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein αI-mediated activation of phosphotyrosine

phosphatase. *Endocrinology* 142: 2369–2380. doi:10.1210/endo.142.6.8190

Gründker, C., Völker, P., Schulz, K.D., & Emons, G., 2000. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist Cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. *Gynecol. Oncol.* 78: 194–202. doi:10.1006/gyno.2000.5863

Gulmann, C., Loring, P., O'Grady, A., & Kay, E., 2004. Miniature tissue microarrays for HercepTest standardisation and analysis. *J. Clin. Pathol.* 57: 1229–1231. doi:10.1136/jcp.2004.018689

H.B. Çiftci, 2015. Structures, Functions and Expressions of GnRH and GnRH Receptor in Peripheral Reproductive Organs and Their Regulation by Estradiol-17β. *Iran. J. Appl. Anim. Sci.* 5: 775–786.

Hall, J.E., 2015. Endocrinology of the Menopause. *Endocrinol. Metab. Clin. North Am.* 44: 485–496. doi:10.1016/j.ecl.2015.05.010

Hanahan, D., 2022. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 12: 31–46. doi:10.1158/2159-8290.CD-21-1059

Hsu, F.D., Nielsen, T.O., Alkushi, A., Dupuis, B., Huntsman, D., Liu, C.L., et al., 2002. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. *Mod. Pathol. an Off. J. United States Can. Acad. Pathol. Inc* 15: 1374–1380. doi:10.1097/01.MP.0000039571.02827.CE

Huang, H., Li, Y.J., Lan, C.Y., Huang, Q.D., Feng, Y.L., Huang, Y.W., et al., 2013. Clinical significance of ascites in epithelial ovarian cancer. *Neoplasma* 60: 546–552. doi:10.4149/neo_2013_071

Ibrahim, T.R., Raouf, S.M.A., Abdelgawad, M., & Elwan, A., 2020. Clinicopathological and Prognostic Value of Immunohistochemical Expression of CD44 (Stem Cell Marker) and Ki67 in Serous Ovarian Cancer. *J. Clin. Diagnostic Res.* 44: 1–7. doi:10.7860/jcdr/2020/43003.13453

Jawhar, N.M.T., 2009. Tissue Microarray: A rapidly evolving diagnostic and research tool. *Ann. Saudi Med.* 29: 123–127. doi:10.4103/0256-4947.51806

Kheiri, S.A., Kunna, A., Babiker, A.Y., Alsuhaibani, S.A., Ahmed, R.Y., & Alsammani, M.A., 2018. Histopathological pattern and age distribution, of malignant ovarian tumor among sudanese ladies. *Open Access Maced. J. Med. Sci.* 6: 237–241. doi:10.3889/OAMJMS.2018.067

Khosravi, S., & Leung, P.C.K., 2003. Differential regulation of gonadotropin-releasing hormone (GnRH)I and GnRHII messenger ribonucleic acid by gonadal steroids in human granulosa luteal cells. *J. Clin. Endocrinol. Metab.* 88: 663–672. doi:10.1210/jc.2002-020866

Köbel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., et al., 2008. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. *PLoS Med.* 5: 1749–1760.

doi:10.1371/journal.pmed.0050232

Koshiyama, M., Matsumura, N., & Konishi, I., 2017. Subtypes of Ovarian Cancer and Ovarian Cancer Screening. *Diagnostics* 7: 1–10. doi:10.3390/diagnostics7010012

Kuhn, E., Kurman, R.J., Sehdev, A.S., & Shih, I.-M., 2012. Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. *Int. J. Gynecol. Pathol.* 31.

Kurman, R.J., & Shih, I.M., 2016. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. *Am. J. Pathol.* 186: 733–747. doi:10.1016/j.ajpath.2015.11.011

Lheureux, S., Gourley, C., Vergote, I., & Oza, A.M., 2019. Epithelial ovarian cancer. *Lancet* 393: 1240–1253. doi:10.1016/S0140-6736(18)32552-2

Limonta, P., Moretti, R.M., Marelli, M.M., & Motta, M., 2003. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. *Front. Neuroendocrinol.* 24: 279–295. doi:https://doi.org/10.1016/j.yfrne.2003.10.003

Lin, T.C., Su, C.Y., Wu, P.Y., Lai, T.C., Pan, W.A., Jan, Y.H., et al., 2016. The nucleolar protein NIFK promotes cancer progression via ck1α/β-catenin in metastasis and ki-67-dependent cell proliferation. *Elife* 5: 1–21. doi:10.7554/eLife.11288

Liu, J., MacCalman, C.D., Wang, Y.L., & Leung, P.C.K., 2009. Promotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways. *Mol. Endocrinol.* 23: 1014–1021. doi:10.1210/me.2008-0451

Liu, Q., Zhou, X., Feng, W., Pu, T., Li, X., Li, F., et al., 2020. Gonadotropin-Releasing Hormone Receptor-Targeted Near-Infrared Fluorescence Probe for Specific Recognition and Localization of Peritoneal Metastases of Ovarian Cancer. *Front. Oncol.* 10: 1–13. doi:10.3389/fonc.2020.00266

Liu, Z., Wang, F., & Chen, X., 2008. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. *Drug Dev. Res.* 69: 329–339. doi:10.1002/ddr.20265

López-Reig, R., & López-Guerrero, J.A., 2020. The hallmarks of ovarian cancer: proliferation and cell growth. *Eur. J. Cancer, Suppl.* 15: 27–37. doi:10.1016/j.ejcsup.2019.12.001

Mahadevappa, A., Krishna, S.M., & Vimala, M.G., 2017. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma 11: 8–12. doi:10.7860/JCDR/2017/24350.9381

Menon, S.S., Guruvayoorappan, C., Sakthivel, K.M., & Rasmi, R.R., 2019. Ki-67 protein as a tumour proliferation marker. *Clin. Chim. Acta* 491: 39–45. doi:10.1016/j.cca.2019.01.011

Miller, I., Min, M., Yang, C., Tian, C., Gookin, S., Carter, D., et al., 2018. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence Graphical Abstract HHS Public Access. *Cell Rep* 24: 1105–1112. doi:10.1016/j.celrep.2018.06.110.Ki67

Moazed, V., Jafari, E., Khandani, B.K., Nemati, A., Roozdar, A., & Razavi, S.A. Ben, 2018. Prognostic significance of reduction in Ki67 index after neoadjuvant chemotherapy in patients with breast cancer in Kerman between 2009 and 2014. *Iran. J. Pathol.* 13: 71–77. doi:10.30699/ijp.13.1.71

Mohapatra, I., Harshini, N., Samantaray, S.R., & Sahitya, K.A., 2021. Immunohistochemical expression of P53 and Ki-67 on epithelial tumors of ovary. *Int. J. Reprod. Contraception, Obstet. Gynecol.* 10: 1005. doi:10.18203/2320-1770.ijrcog20210724

Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H., 2019. Ovarian cancer in the world: Epidemiology and risk factors. *Int. J. Womens. Health* 11: 287–299. doi:10.2147/IJWH.S197604

Morgan, K., Conklin, D., Pawson, A.J., Sellar, R., Ott, T.R., & Millar, R.P., 2003. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. *Endocrinology* 144: 423–436. doi:10.1210/en.2002-220622

Na, T.Y., Schecterson, L., Mendonsa, A.M., & Gumbiner, B.M., 2020. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. *Proc. Natl. Acad. Sci. U. S. A.* 117: 5931–5937. doi:10.1073/pnas.1918167117

National Library of Medicine, 2022. GNRH2 gonadotropin releasing hormone 2 [Homo sapiens (human)] [WWW Document]. *Natl. Cent. Biotechnol. Inf.* URL https://www.ncbi.nlm.nih.gov/gene/2797 (accessed 3.7.23).

Neill, J.D., Musgrove, L.C., & Duck, L.W., 2004. Newly recognized GnRH receptors: Function and relative role. *Trends Endocrinol. Metab.* 15: 383–392. doi:10.1016/j.tem.2004.08.005

Noela, F., & Nuryanto, H.K., 2016. Epidemiology Data of Ovarian Cancer in Dr . Cipto Mangunkusumo Hospital , Jakarta. *Indones J Obs. Gynecol* 4: 0–5.

Novus Biological, 2022. Tissue Microarray Construction [WWW Document]. URL https://www.novusbio.com/tissue-microarrays

Page, C., Köbel, M., Ladurantaye, M., Rahimi, K., Madore, J., Babinszky, S., et al., 2013. Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. *Biopreserv. Biobank.* 11: 83–93. doi:10.1089/bio.2012.0044

Park, S., Han, J.M., Cheon, J., Hwang, J.I., & Seong, J.Y., 2014. Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist.

PLoS One 9. doi:10.1371/journal.pone.0099723

Pawson, A.J., Morgan, K., Maudsley, S.R., & Millar, R.P., 2003. Type II gonadotrophin-releasing hormone (GnRH-II) in reproductive biology. *Reproduction* 126: 271–278. doi:10.1530/rep.0.1260271

Pei, D.S., Qian, G.W., Tian, H., Mou, J., Li, W., & Zheng, J.N., 2012. Analysis of human Ki-67 gene promoter and identification of the Sp1 binding sites for Ki-67 transcription. *Tumor Biol.* 33: 257–266. doi:10.1007/s13277-011-0277-z

Pfleger, K.D.G., Bogerd, J., & Millar, R.P., 2002. Conformational constraint of mammalian, chicken, and salmon GnRHs, but not GnRH II, enhances binding at mammalian and nonmammalian receptors: Evidence for preconfiguration of GnRH II. *Mol. Endocrinol.* 16: 2155–2162. doi:10.1210/me.2002-0159

Pignata, S., Cecere, S.C., Du Bois, A., Harter, P., & Heitz, F., 2017. Treatment of recurrent ovarian cancer. *Ann. Oncol.* 28: viii51–viii56. doi:10.1093/annonc/mdx441

Pölcher, M., Friedrichs, N., Rudlowski, C., Fimmers, R., Keyver-Paik, M.-D., Kübler, K., et al., 2010. Changes in Ki-67 Labeling Indices During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Are Associated With Survival. *Int. J. Gynecol. Cancer* 20: 555–560. doi:10.1111/IGC.0b013e3181c104c0

Poon, S.L., Lau, M.T., Hammond, G.L., & Leung, P.C.K., 2011. Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via β-catenin signaling in ovarian cancer cells. *Endocrinology* 152: 764–772. doi:10.1210/en.2010-0942

Purbadi, S., Anggraeni, T.D., & Vitria, A., 2021. Early stage epithelial ovarian cancer metastasis through peritoneal fluid circulation 1–5.

Qiu, D., Cai, W., Zhang, Z., Li, H., & Zhou, D., 2019. High Ki-67 expression is significantly associated with poor prognosis. *Arch. Gynecol. Obstet.*

Ravindran, F., & Choudhary, B., 2021. Ovarian Cancer: Molecular Classification and Targeted Therapy, in: Webber, B.C.E.-G.-Y.H.E.-K. (Ed.), . IntechOpen, Rijeka, p. Ch. 1. doi:10.5772/intechopen.95967

Rebelo, S., Santos, M., Martins, F., da Cruz e Silva, E.F., & da Cruz e Silva, O.A.B., 2015. Protein phosphatase 1 is a key player in nuclear events, Cellular Signalling. Elsevier B.V. doi:10.1016/j.cellsig.2015.08.007

Rödel, F., Zhou, S., Győrffy, B., Raab, M., Sanhaji, M., Mandal, R., et al., 2020. The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. *Front. Oncol.* 10: 1–10. doi:10.3389/fonc.2020.558932

Ruengwanichayakun, P., 2021. Histochemical scoring assessment (H-score). *Asian*

Arch. Pathol. 13: 13–14.

Safitri, W.R., 2016. Analisis Korelasi Pearson Dalam Menentukan Hubungan Antara Kejadian Demam Berdarah Dengue Dengan Kepadatan Penduduk Di Kota Surabaya Pada Tahun 2012-2014. *J. Ilm. Keperawatan (Scientific J. Nursing)* 2: 21–29.

Saglam, O., 2022. Endometrioid Carcinoma [WWW Document]. URL https://www.pathologyoutlines.com/topic/ovarytumorendometrioidcarcinoma.html. (accessed 7.24.22).

Schildkraut, J.M., Halabi, S., Bastos, E., Marchbanks, P.A., McDonald, J.A., & Berchuck, A., 2000. Prognostic factors in early-onset epithelial ovarian cancer: A population-based study. *Obstet. Gynecol.* 95: 119–127. doi:10.1016/S0029-7844(99)00535-9

Sehouli, J., Braicu, E.I., Richter, R., Denkert, C., Jank, P., Jurmeister, P.S., et al., 2019. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. *Hum. Pathol.* 85: 299–308. doi:10.1016/j.humpath.2018.10.020

Shi, Y., He, D., Hou, Y., Hu, Q., Xu, C., Liu, Y., et al., 2013. An alternative high output tissue microarray technique. *Diagn. Pathol.* 8: 9. doi:10.1186/1746-1596-8-9

Sindiani, A., Obeidat, B., Hamadeh, L., Alghazo, S., Al-Mohtaseb, A., & Alshdaifat, E., 2020. A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study. *Ann. Med. Surg.* 59: 254–257. doi:https://doi.org/10.1016/j.amsu.2020.09.043

Singh, N., & Kamath, S.M., 2022. Ki-67 Immunostaining in Epithelial Ovarian Tumors with Clinicopathological Correlation 19–26.

Singla, A., 2019. Epidemiology and Risk Factors for Ovarian Cancer, in: Preventive Oncology for the Gyne. Springer Singapore, Singapore, pp. 223–231.

Sobecki, M., Mrouj, K., Colinge, J., Gerbe, F., Jay, P., Krasinska, L., et al., 2017. Cell-cycle regulation accounts for variability in Ki-67 expression levels. *Cancer Res.* 77: 2722–2734. doi:10.1158/0008-5472.CAN-16-0707

Soliman, N.A., & Yussif, S.M., 2016. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol. Med.* 13: 496–504. doi:10.20892/j.issn.2095-3941.2016.0066

Stewart, A.J., Katz, A.A., Millar, R.P., & Morgan, K., 2009. Retention and silencing of prepro-GnRH-II and type II GnRH receptor genes in mammals. *Neuroendocrinology* 90: 416–432. doi:10.1159/000233303

Sun, X., & Kaufman, P.D., 2018. Ki-67: more than a proliferation marker.

Chromosoma 127: 175–186. doi:10.1007/s00412-018-0659-8

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71: 209–249. doi:10.3322/caac.21660

Sung Keun Kang, Tai, C.J., Nathwani, P.S., Choi, K.C., & Leung, P.C.K., 2001. Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells. *Endocrinology* 142: 671–679. doi:10.1210/en.142.2.671

Suo, L., Chang, X., Xu, N., & Ji, H., 2019. The anti-proliferative activity of GnRH through downregulation of the Akt/ERK pathways in pancreatic cancer. *Front. Endocrinol. (Lausanne).* 10: 1–12. doi:10.3389/fendo.2019.00370

Terada, K.Y., Ahn, H.J., & Kessel, B., 2016. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. *J. Gynecol. Oncol.* 27: 1–8. doi:10.3802/jgo.2016.27.e25

Tian, H., Qian, G.W., Li, W., Chen, F.F., Di, J.H., Zhang, B.F., et al., 2011. A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. *Tumor Biol.* 32: 273–283. doi:10.1007/s13277-010-0119-4

Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., et al., 2018. Ovarian cancer statistics, 2018. *CA. Cancer J. Clin.* 68: 284–296. doi:10.3322/caac.21456

Uxa, S., Castillo-Binder, P., Kohler, R., Stangner, K., Müller, G.A., & Engeland, K., 2021. Ki-67 gene expression. *Cell Death Differ.* 28: 3357–3370. doi:10.1038/s41418-021-00823-x

Vagnarelli, P., Ribeiro, S., Sennels, L., Sanchez-Pulido, L., de Lima Alves, F., Verheyen, T., et al., 2011. Repo-Man Coordinates Chromosomal Reorganization with Nuclear Envelope Reassembly during Mitotic Exit. *Dev. Cell* 21: 328–342. doi:10.1016/j.devcel.2011.06.020

Varghese, F., Bukhari, A.B., Malhotra, R., & De, A., 2014. IHC profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. *PLoS One* 9. doi:10.1371/journal.pone.0096801

Wang, J., Liu, Q., Zhou, X., He, Y., Guo, Q., Shi, Q., et al., 2017. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker. *Tumor Biol.* 39. doi:10.1177/1010428317706479

Wang, M.J., Pei, D.S., Qian, G.W., Yin, X.X., Cheng, Q., Li, L.T., et al., 2011. P53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells. *Tumor Biol.* 32: 905–912. doi:10.1007/s13277-011-0191-4

Webb, P.M., & Jordan, S.J., 2017. Epidemiology of epithelial ovarian cancer. *Best*

Pract. Res. Clin. Obstet. Gynaecol. 41: 3–14. doi:10.1016/j.bpobgyn.2016.08.006

Wentzensen, N., Poole, E.M., Trabert, B., White, E., Arslan, A.A., Patel, A. V, et al., 2016. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. *J. Clin. Oncol.* 34: 2888–2898. doi:10.1200/JCO.2016.66.8178

White, R.B., Eisen, J.A., Kasten, T.L., & Fernald, R.D., 1998. Second gene for gonadotropin-releasing hormone in humans. *Proc. Natl. Acad. Sci. U. S. A.* 95: 305–309. doi:10.1073/pnas.95.1.305

Yousefi, M., Dehghani, S., Nosrati, R., Ghanei, M., Salmaninejad, A., Rajaie, S., et al., 2020. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. *Cell. Oncol. (Dordr).* 43: 515–538. doi:10.1007/s13402-020-00513-9

Yu, H., Wang, J., Wu, B., li, J., & Chen, R., 2023. Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis. *J. Ovarian Res.* 16: 1–10. doi:10.1186/s13048-023-01102-8

Zhou, J., Sun, J.Y., Wu, S.G., Wang, X., He, Z.Y., Chen, Q.H., et al., 2016. Risk factors for lymph node metastasis in ovarian cancer: Implications for systematic lymphadenectomy. *Int. J. Surg.* 29: 123–127. doi:10.1016/j.ijsu.2016.03.039

Zou, J., Lei, T., Guo, P., Yu, J., Xu, Q., Luo, Y., et al., 2019. Mechanisms shaping the role of ERK1/2 in cellular senescence (Review). *Mol. Med. Rep.* 19: 759–770. doi:10.3892/mmr.2018.9712

Zucha, M., Silawani, S., Dewanto, A., Widad, S., Taufiqurrachman, I., Kusumanto, A., et al., 2022. Expression of GnRH Receptor Type-II Correlates with Proliferation Activity in Endometriosis. *Int. J. Infertil. Fetal Med.* 13: 37–41. doi:10.5005/jp-journals-10016-1253